Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin) In Canada
Halozyme Therapeutics announced that Roche has received approval from Health Canada for a subcutaneous (SC) formulation of trastuzumab (Herceptin SC) for the treatment of patients with…
Read More...
Read More...